Ligand Pharmaceuticals (LGND) Stock Price
$120.7 0%
to add to portfolio
AI Score

-
Alternative
6 -
Fundamental
7 -
Technical
7
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Ligand Pharmaceuticals, AI stock picks, stock alerts and much more.
LGND AI Stock Analysis
AI stock analysis for LGND is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Ligand Pharmaceuticals (LGND) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Ligand Pharmaceuticals (LGND) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Ligand Pharmaceuticals (LGND), currently trading at $120.7, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About LGND

-
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide.
-
Symbol
LGND
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.3B
Similar Stocks
![]() |
Catalyst Pharmaceuticals CPRX |
$21.62 2% |
6 |
![]() |
Inovio Pharmaceuticals INO |
$2.24 0.9% |
2 |
![]() |
Moderna MRNA |
$35.53 5.3% |
4 |
![]() |
Anavex Life Sciences AVXL |
$8.35 3.8% |
6 |
![]() |
BridgeBio Pharma BBIO |
$36.85 0.1% |
6 |
LGND Alternative Data
Web Traffic
Ligand Pharmaceuticals receives an estimated 4455 monthly visitors to ligand.com.
-
Web Traffic
4455
-
Change from Previous Month
1.5%
-
3 Month Change
23.3%
-
YoY Change
23.3%
News Mentions
Ligand Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
50%
Reddit Mentions
Ligand Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
Twitter Followers
Ligand Pharmaceuticals has 10,628 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.2% over the last month.
-
Twitter Followers
10628
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.5%
LinkedIn Followers
6,592 are following Ligand Pharmaceuticals on LinkedIn, up by 1.1% over the last month.
-
LinkedIn Followers
6592
-
Daily Change
0%
-
1 Month Change
1.1%
-
3 Month Change
3.7%
Job Postings
Ligand Pharmaceuticals currenly has an estimated 1 open job postings.
-
Job Postings
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, Ligand Pharmaceuticals has 120 employees, down by -2.4% over the last month.
-
LinkedIn Employees
120
-
Daily Change
0%
-
1 Month Change
2.4%
-
3 Month Change
4.3%
Business Outlook
-
Business Outlook
58
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
LGND Financials
LGND Key Metrics
-
Total Revenue
$51.8M
-
Net Income
-$7.2M
-
Earnings per Share
-$0.39
-
Free cash flow
$22.3M
-
EBITDA
$3.1M
-
EBITDA Ratio
0.0606616
-
Total Assets
$954.9M
LGND 2-year Revenue & Income
LGND 2-year Free Cash Flow
LGND Technicals
LGND SMA
LGND RSI
FAQ
What's the current price of Ligand Pharmaceuticals (LGND) Stock?
The price of an Ligand Pharmaceuticals (LGND) share is $120.7.
What's the market cap of Ligand Pharmaceuticals?
The current market cap of Ligand Pharmaceuticals is 2.3B.
Should I buy or sell LGND?
Multiple alternative data signals suggest that Ligand Pharmaceuticals stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Ligand Pharmaceuticals a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Ligand Pharmaceuticals stock. The bullish indicators suggest that Ligand Pharmaceuticals' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Ligand Pharmaceuticals (LGND) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Ligand Pharmaceuticals stock, given the bullish outlook.
What are some stocks similar to Ligand Pharmaceuticals (LGND) that investors often compare it to?
Ligand Pharmaceuticals (LGND) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Ligand Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Ligand Pharmaceuticals' stock price to be around $128.5 in 2026. Starting from the current price of $120.7, this represents a 6.5% change in price, indicating a bullish outlook for the stock.
How to buy Ligand Pharmaceuticals (LGND) Stock?
Ligand Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Ligand Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.